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Abstract
Introduction: Although centrifugation is performed in almost every blood sample, recommendations on duration and g-force are heterogeneo-
us and mostly based on expert opinions. In order to unify this step in a fully automated laboratory, we aimed to evaluate different centrifugation 
settings and their influence on the results of routine clinical chemistry analytes. 
Materials and methods: We collected blood from 41 healthy volunteers into BD Vacutainer PST II-heparin-gel- (LiHepGel), BD Vacutainer SST II-
serum-, and BD Vacutainer Barricor heparin-tubes with a mechanical separator (LiHepBar). Tubes were centrifuged at 2000xg for 10 minutes and 
3000xg for 7 and 5 minutes, respectively. Subsequently 60 and 21 clinical chemistry analytes were measured in plasma and serum samples, respec-
tively, using a Roche COBAS instrument. 
Results: High sensitive Troponin T, pregnancy-associated plasma protein A, ß human chorionic gonadotropin and rheumatoid factor had to be 
excluded from statistical evaluation as many of the respective results were below the measuring range. Except of free haemoglobin (fHb) measure-
ments, no analyte result was altered by the use of shorter centrifugation times at higher g-forces. Comparing LiHepBar to LiHepGel tubes at different 
centrifugation setting, we found higher lactate-dehydrogenase (LD) (P = 0.003 to < 0.001) and lower bicarbonate values (P = 0.049 to 0.008) in the 
latter. 
Conclusions: Serum and heparin samples may be centrifuged at higher speed (3000xg) for a shorter amount of time (5 minutes) without alteration 
of the analytes tested in this study. When using LiHepBar tubes for blood collection, a separate LD reference value might be needed.
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Introduction
Apart from sample collection and transportation, 
sample preparation by centrifugation is one of the 
most critical steps in the pre-analytical phase. In 
order to obtain the best sample material quality 
for laboratory analysis centrifugation time, speed 
and temperature are crucial. Prolonged centrifu-
gation at high speed might lead to haemolysis or 
structural damage to the measurand whereas brief 
low speed centrifugations may lead to insufficient 
separation of plasma or serum from cellular blood 
components (1). As a consequence, laboratory 
analyses might be altered due to chromatic inter-
ferences, loss of analytes being metabolized or 
consumed and interference by residual cellular 
components such as platelets, leucocytes or their 
components (2-5). In addition to these quality is-
sues of sample preparation, many if not all labora-
tories have to keep turnaround times (TATs) in the 
total testing process as short as possible in order 
to rapidly diagnose the patient. As the duration for 
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the analytical process usually is invariably deter-
mined by the respective analytical device, reduc-
ing the TAT within the laboratory may be achieved 
by optimizing the centrifugation conditions. One 
obstacle in such optimization attempts is the fact 
that these conditions depend on the type of sam-
ple or even on the type of separator. For example, 
coagulation tubes should usually be centrifuged 
for a longer period of time than samples for clini-
cal chemistry analyses to retrieve platelet poor or 
even platelet “free” plasma (6). In current recom-
mendations on sample centrifugation, there is a 
big variety in terms of centrifugation time, speed 
and temperature, ranging from 10 to 20 minutes 
and 1500 to 3000xg at 15 to 25°C, respectively (6-
13). These parameters also change depending on 
the gel composition used in the specific country 
with g-forces as low as 1000xg (14). The manufac-
turer of the newly introduced BD-Barricor tube, 
which uses a mechanical separator instead of a gel 
barrier, claims that these tubes may be centrifuged 
at higher speed and shorter time, recommending 
centrifugation for 5 minutes at 3000xg or only 3 
minutes at 4000xg. 
Often it is referred to the centrifugation recom-
mendation of blood collection tube manufactur-
ers (15). However, picturing the number of possi-
ble laboratory parameters on all of the possible 
analytical platforms, it seems unlikely that provid-
ers of blood collection tubes are able to validate 
every single one of these combinations. Even if 
such a validation would be available, tube manu-
facturers would have to find a way of validating 
also newly introduced parameters measured in 
plasma or serum, collected into one of their tubes. 
Therefore tube vendors most probably recom-
mend to centrifuge for a longer duration than nec-
essary to prevent incomplete plasma/serum sepa-
ration and to cover most if not all possible analyti-
cal combinations (11-13). We therefore believe that 
manufacturers of analytical devices or assays 
should validate sample preparation settings for 
their products, taking tube characteristics in terms 
of material or resistance to temperature and g-
forces into account, instead of relying on recom-
mendations of tube manufacturers. However, 
these validation data are often lacking. 
In our hospital Vacutainer, LH PSTTM II lithium hep-
arin and Vacutainer, SSTTM II Advance serum tubes 
as well as the Vacutainer BarricorTM tubes (all tubes 
from Becton Dickinson, Franklin Lakes, NJ/USA), 
which are used in our emergency department, are 
centrifuged for 10 minutes at 2000xg. As we aim to 
implement fully automated pre-analytical and an-
alytical processes, we were seeking to achieve a 
unified and standardized sample centrifugation 
with the shortest time possible for most if not all 
sample types without significantly altering plas-
ma/serum quality. In the field of haemostasis, re-
spective evaluations of shortened centrifugation 
time at higher g-forces are available in recent liter-
ature (3,16-18). For clinical chemistry parameters 
however, these data are scarce (19). 
In this study we therefore aimed to evaluate a 
standardized sample preparation protocol for clin-
ical chemistry analyses by comparing different 
centrifugation conditions in heparin-gel-, serum- 
and Barricor tubes. 
Materials and methods
This study was conducted at the Department of 
Laboratory Medicine and Microbiology of the Uni-
versity Hospital Salzburg between August and No-
vember 2016.
After approval by the local ethics committee (Pro-
tocol number 415-E/2028/9-2016) and a written in-
formed consent of every participant, three Lithi-
um-Heparin gel tubes (LiHepGel) (BD Vacutainer, 
LH PSTTM II, 16x100mm, 8ml REF:367378), three se-
rum gel tubes (BD Vacutainer, SSTTM II Advance, 
16x100mm, 8ml REF: 367953) and two Lithium 
Heparin tubes using a mechanical separator (Li-
HepBar) (BD Vacutainer Barricor LH Plasma, 
13x100mm, 5ml REF: 365039) were drawn from 41 
healthy volunteers (17 males and 24 females with a 
median (range) age of 42 (20-74) years) according 
to current recommendations (20). All blood collec-
tions were performed using a 21G winged safety 
blood collection set (GBO Vacuette safety blood 
collection set, 19cm, REF 450081; Greiner BioOne, 
Kremsmünster, Austria). The order of sample tube 
collection was randomized in every participant 
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and the tourniquet was removed while the first 
tube was filled. All samples were mixed according 
to the manufacturer’s instructions. LiHepGel and 
LiHepBar tubes were processed immediately after 
sample collection. Serum samples were stored at 
room temperature in an upright position for 30 
minutes to allow the sample to clot appropriately 
before further processing (21). Always one of the 
respective LiHepGel and serum tubes were centri-
fuged at 2000xg for 10 minutes, as well as at 
3000xg for 7 minutes and at 3000xg for 5 minutes. 
The two LiHepBar tubes were centrifuged at 
2000xg for 10 minutes and at 3000xg for 5 min-
utes (Figure 1). There was no LiHepBar tube being 
centrifuged at 3000xg for 7 minutes as recommen-
dations emphasize an even shorter time of 5 min-
utes at this g-force. High throughput centrifuges 
as used in our laboratory mostly reach a maximum 
of about 3000xg, therefore no higher g-forces 
were evaluated. All centrifugations were per-
formed on Hettich centrifuges (Rotanta 460R and 
Rotixa 500RS, Hettich Lab Technology, Tuttlingen, 
Germany) using a swing-out rotor at a tempera-
ture of 22°C. Sixty analytes were measured in hep-
arin plasma and another 21 analytes were meas-
ured in serum. Analyses for all of the 81 parame-
ters, measurable on the Roche COBAS 8000 device 
(Roche Diagnostics, Rotkreuz, Switzerland) were 
performed in duplicate, immediately after centrif-
ugation (Table 1). 
Twice daily quality controls (QC) controls within 
the target range and Westgard rules (13s, 12s, 22s, 
R4s and 2of32s) were a premise for analyses of the 
samples. Control samples from two different man-
ufacturers were used (Roche Diagnostics, Basel, 
Switzerland and Bio-Rad Laboratories, Hercules, 
USA). Coefficients of variations (CV) for QC of all 
analytes tested are shown in Table 1 and Table 2. 
For calculation of these CVs we used data from the 
current lot of the low level control of respective 
parameters. If this lot was in use for less than two 
weeks, we additionally used the data of the previ-
ous lot. Haemolysis index (HI) measurements are 
referred to as free haemoglobin (fHb), since re-
spective measurements from this instrument are 
directly correlated with an HI of 1 being equal to a 
fHb value of 0.01 g/L (22,23). If test results were be-
Figure 1. Sample collection and preparation workflow.
LiHepGel – vacuum lithium heparin gel tubes. LiHepBar – vacu-
um lithium heparin Barricor tubes. 
low the measurement range, all according values 
of the other centrifugation settings from this spe-
cific sample were not considered for further analy-
sis. If results from more than 50% of samples had 
to be excluded, the respective analyte was elimi-
nated from statistical analyses. 
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Parameter, unit N* CV (%)†
Centrifugation conditions per tube type
P2000xg/10min 2000xg/10min 3000xg/7min 3000xg/5min 3000xg/5min
LiHepGel LiHepBar LiHepGel LiHepGel LiHepBar
Chloride, mmol/L 41 1.6 98 (2) 98 (3) 98 (3) 98 (3) 98 (3) 1.0
Bicarbonate, mmol/L 41 11.1 28 (2) 29 (2) 28 (2) 28 (2) 28 (2) 0.286
Potassium, mmol/L 41 1.1 4 (0.3) 4 (0.2) 4 (0.3) 4 (0.3) 4 (0.3) 1.0
Sodium, mmol/L 41 1.0 138 (3) 138 (2) 138 (2) 138 (2) 138 (2) 1.0
Urea, mmol/L 41 18.9 4 (2) 4 (2) 4 (2.2) 4 (2) 4 (2) 1.0
Creatinine, µmol/L 41 6.3 71 (22.1) 71 (26.6) 71 (22.1) 71 (17.7) 71 (26.6) 1.0
Creatinine estimated 
glomerular filtration rate, 
mL/min/1.73m2
41 / 94 (16) 95 (17) 95 (16) 95 (16) 96 (16) 1.0
Calcium, mmol/L 41 5.0 2.32 (0.14) 2.31 (0.11) 2.32 (0.12) 2.32 (0.11) 2.31 (0.13) 1.0
Total protein, g/L 41 4.6 73 (6) 74 (6) 73 (7) 74 (5) 73 (6) 1.0
Glucose, mmol/L 41 4.8 94 (11) 93 (12) 94 (10) 93 (11) 93 (9) 1.0
C-reactive protein, mg/L 24 (17) 5.5 2 (3.25) 2 (3.25) 2 (3.25) 2 (3.25) 2 (3.25) 1.0
High sensitive C-reactive 
protein, mg/L 41 8.7 0.9 (1.4) 0.9 (1.5) 0.9 (1.4) 0.9 (1.6) 0.9 (1.5) 1.0
Uric acid, mmol/L 41 4.9 0.29 (0.12) 0.29 (0.12) 0.29 (0.11) 0.29 (0.11) 0.29 (0.11) 1.0
Phosphorus, mmol/L 41 6.5 0.97 (0.22) 0.97 (0.24) 0.96 (0.22) 0.98 (0.22) 0.97 (0.21) 1.0
Magnesium, mmol/L 41 5.5 0.82 (0.07) 0.82 (0.07) 0.82 (0.07) 0.83 (0.06) 0.82 (0.06) 1.0
Bilirubin total, µmol/L 41 4.0 8.6 (5.1) 8.6 (5.1) 8.6 (6.8) 8.6 (5.1) 8.6 (5.1) 1.0
Bilirubin direct, µmol/L 41 5.8 3.4 (2.4) 3.4 (0.7) 3.4 (0.7) 3.4 (0.9) 3.4 (0.9) 1.0
Cholesterol, mmol/L 41 5.8 5 (1.1) 5 (1.1) 5 (1.2) 4.9 (1.1) 5 (1) 1.0
Triglycerides, mmol/L 41 4.8 1 (0.6) 1 (0.6) 1.1 (0.6) 1 (0.6) 1.1 (0.6) 1.0
HDL-Cholesterol, mmol/L 41 6.2 1.8 (0.6) 1.8 (0.6) 1.8 (0.6) 1.8 (0.6) 1.9 (0.6) 1.0
Apo-Lipoprotein B, mg/L 41 3.9 940 (340) 940 (320) 950 (310) 930 (320) 940 (310) 1.0
Lipoprotein (a), nmol/L 32 (9) 4.0 27.8 (90) 28.8 (91.4) 28.2 (88.9) 27.8 (90.1) 28.4 (91.7) 1.0
Aspartate-transaminase, 
U/L 41 5.6 21 (8) 20 (9) 22 (8) 22 (9) 22 (7) 1.0
Alanine-transaminase, 
U/L 41 9.1 21 (14) 21 (11) 21 (12) 21 (14) 20 (13) 1.0
Lactate-dehydrogenase, 
U/L 41 1.6 164 (18) 158 (22) 170 (21) 171 (20) 157 (17) < 0.001
Alkaline-phosphatase, 
U/L 41 6.7 57 (19) 56 (14) 56 (17) 55 (19) 57 (18) 1.0
γ-Glutamyl-transferase, 
U/L 41 2.7 15 (12) 14 (13) 14 (14) 14 (13) 14 (14) 1.0
Cholinesterase, U/L 41 2.2 74 (27) 73 (27) 74 (27) 74 (27) 73 (29) 1.0
Glutamate- 
dehydrogenase, U/L 40 (1) 4.8 2.3 (1.8) 2.6 (2.3) 2.5 (2.0) 2.6 (1.8) 2.5 (1.6) 1.0
Amylase, U/L 41 4.3 63 (21) 65 (21) 64 (21) 63 (21) 65 (20) 1.0
Lipase, U/L 41 9.7 32 (18) 33 (17) 33 (16) 33 (17) 32 (17) 1.0
Creatin-kinase, U/L 41 2.1 101 (90) 98 (92) 98 (92) 99 (92) 101 (94) 1.0
Table 1. Comparison of laboratory values measured in plasma for different centrifugation conditions and tube type
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Parameter, unit N* CV (%)†
Centrifugation conditions per tube type
P2000xg/10min 2000xg/10min 3000xg/7min 3000xg/5min 3000xg/5min
LiHepGel LiHepBar LiHepGel LiHepGel LiHepBar
Iron, µmol/L 41 2.4 17.2 (8.4) 17.4 (8.6) 17.2 (8.6) 17.2 (8.2) 17.4 (8.6) 1.0
Transferrin, µmol/L 41 2.0 32.1 (6.2) 32.5 (6) 32.6 (6.3) 32.1 (6.3) 32.3 (6.8) 1.0
Soluble transferrin 
receptor, nmol/L 41 2.9 34.9 (14.4) 34.1 (14) 34.1 (17.1) 34.6 (13.9) 34.3 (15.7) 1.0
Ferritin, µg/L 41 12.2 80 (120) 80 (127) 80 (124) 81 (126) 79 (126) 1.0
Fructosamine, µmol/L 41 12.7 256 (41) 261 (38) 256 (44) 258 (37) 264 (39) 1.0
Free haemoglobin 
plasma, g/L 41 / 0.06 (0.04) 0.05 (0.02) 0.07 (0.04) 0.07 (0.02) 0.04 (0.03) < 0.001
Icterus index plasma, 
index 41 / 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1.0
Lipemia index plasma, 
index 41 / 10 (6) 8 (6) 9 (5) 12 (6) 11 (5) 1.0
Creatin-kinase MB 
immunologic, µg/L 41 1.7 1.8 (1.2) 1.8 (1.2) 1.8 (1.1) 1.8 (1.2) 1.8 (1.2) 1.0
Myoglobin, µg/L 41 8.3 45 (14) 45 (15) 45 (15) 45 (15) 45 (14) 1.0
N-terminal pro brain 
natriuretic peptide, pmol/L 40 (1) 2.1 4.4 (4.7) 4.4 (4.4) 4.4 (4.3) 4.3 (4.6) 4.4 (4.2) 1.0
Thyroid stimulating 
hormone, mU/L 41 5.3 1.96 (1.17) 1.91 (1.15) 1.97 (1.12) 1.92 (1.2) 1.95 (1.13) 1.0
Free Triiodothyronine, 
pmol/L 41 6.4 4.7 (0.6) 4.6 (0.6) 4.6 (0.7) 4.6 (0.7) 4.6 (0.6) 1.0
Albumin, g/L 41 5.1 46 (3) 47 (3) 46 (3) 46 (3) 46 (4) 1.0
Complement C3, g/L 41 7.4 1.1 (0.2) 1.1 (0.2) 1.1 (0.2) 1.1 (0.2) 1.1 (0.2) 1.0
Complement C4, g/L 41 6.9 0.25 (0.12) 0.25 (0.12) 0.26 (0.11) 0.24 (0.13) 0.25 (0.11) 1.0
Alpha 1 – antitrypsin, µmol/L 41 4.9 24 (5) 24 (5) 24 (5) 24 (5) 24 (5) 1.0
Haptoglobin, g/L 41 6.2% 1.11 (0.66) 1.13 (0.66) 1.1 (0.66) 1.14 (0.69) 1.15 (0.65) 1.0
Ceruloplasmin, µmol/L 41 4.3% 1.5 (0.3) 1.5 (0.3) 1.5 (0.3) 1.5 (0.3) 1.5 (0.3) 1.0
Interleukin 6, pg/mL 41 1.9% 3.8 (1.5) 3.6 (1.3) 3.5 (1.3) 3.6 (1.3) 3.6 (1.6) 1.0
Data are presented as median and interquartile range. P < 0.05 was considered statistically significant. *Number of individual 
samples used for calculation. In those parameters where this value is less than 41, some of the samples had measured values below 
the measuring range of the respective assay. The number of excluded samples, where applicable, are shown in parentheses. †All 
assays were performed on a COBAS 8000 instrument (Roche Diagnostics) using only proprietary reagents. CVs of day-to-day QC 
control values of the respective parameter. LiHepGel – Lithium Heparin plasma from tubes with gel separator. LiHepBar – Lithium 
Heparin plasma from tubes with mechanical separator. CV – coefficient of variation.
Table 1. Comparison of laboratory values measured in plasma for different centrifugation conditions and tube type - continued
Statistical analysis
Linear mixed effect modelling with Benjamini-
Hochberg multiple testing correction was per-
formed for different centrifugation conditions 
(fixed effects for centrifugation condition and sex, 
random effect for replicate). As a post-hoc test for 
our linear mixed effects modelling we calculated 
pairwise differences of least squares means for the 
fixed effects of interest. For the parameters with 
statistically significant differences, agreement 
analyses using the total allowable error (derived 
from the Ricos criteria on biological variation) as 
cut-off for the total deviation index (TDI) and tar-
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geting at a coverage probability (CP) of 80% were 
performed as suggested by Barnhart et al. (24,25). 
Normality testing was done using the Anderson 
Darling test. All statistical analyses were performed 
with SPSS 23.0 (SPSS Inc. Chicago, USA), R v.3.4.1 
(The R Foundation, Vienna, Austria) and python 
scripts (Python Software Foundation, Python Lan-
guage Reference, version 3.6). A-priori sample size 
calculation was performed using G-Power V3.1.9.2 
(Heinrich-Heine-University, Düsseldorf, Germany) 
yielding a statistical power of 0.8 (26).
Results
Measurements of C-reactive protein (CRP), lipopro-
tein a (Lp(a)), N-terminal pro brain natriuretic pep-
tide (NT-proBNP), glutamate-dehydrogenase 
(GLDH), anti-streptolysin O (ASL), anti-Müller hor-
mone (AMH), carcinoembryonic antigen (CEA) and 
alpha fetoprotein (AFP) yielded values below the 
measuring range in some samples. Subsequently, 
respective samples were not used for further cal-
culations. Since samples were collected in a 
healthy group of volunteers, high sensitive Tro-
ponin T (hsTnT), pregnancy-associated plasma pro-
tein A (PAPP-A), ß human chorionic gonadotropin 
(ßHCG) and rheumatoid factor (RF) were below the 
measuring range in over 50% of study participants 
samples and were therefore excluded from calcu-
lations. For all other parameters, values within the 
measuring range could be obtained in samples of 
all 41 subjects (Table 1 for analytes measured in 
Parameter N* CV (%)†
Centrifugation conditions
P
2000xg/10min 3000xg/7min 3000xg/5min
Free haemoglobin, g/L 41 / 0.05 (0.03) 0.07 (0.04) 0.07 (0.03) 0.001
Icterus index, index 41 / 1 (0) 1 (0) 1 (0) 0.99
Lipemia index serum, index 41 / 5 (4) 6 (5) 6 (5) 0.99
Anti-Müllerian hormone, pmol/L 37 (4) 4.4 25.7 (23.5) 25.7 (23.5) 25.7 (23.5) 0.99
Prealbumin, µmol/L 41 5.7 4.8 (1.4) 4.9 (1.1) 4.8 (1.5) 0.99
Carcinoembryonic antigen, U/L 38 (3) 10.2 23.7 (16.1) 23.7 (14.8) 23.7 (14.8) 0.99
Alpha Fetoprotein, U/L 38 (3) 7.4 19.9 (13.1) 19.9 (14.5) 19.9 (12.9) 0.99
Cytokeratin fragment 21-1, µg/L 41 6.1 1.2 (0.7) 1.2 (0.8) 1.2 (0.7) 0.99
Cancer-Antigen 125, U/L 41 5.7 120 (60) 120 (80) 120 (70) 0.99
Cancer-Antigen19-9, U/L 41 6.2 70 (150) 70 (150) 60 (150) 0.99
Cancer-Antigen 15-3, U/L 41 6.4 170 (110) 170 (100) 170 (110) 0.99
S100 protein, µg/L 41 7.2 0.05 (0.02) 0.05 (0.02) 0.05 (0.02) 0.99
Neuron specific enolase, µg/L 41 6.2 11 (3) 12 (3) 12 (3) 0.71
Cancer-Antigen 72-4, U/L 41 6.5 13 (37) 13 (36) 13 (37) 0.99
Cystatin C, nmol/L 41 2.9 62.9 (11.2) 62.9 (12) 62.9 (12.7) 0.99
Cystatin C estimated glomerular filtration rate, mL/
min/1.73m2
41 / 97 (19) 99 (19) 98 (20) 0.99
Soluble fms-like tyrosine kinase-1, pg/mL 41 16.0 89.4 (11.7) 89.9 (11) 88.8 (13.1) 0.99
Placental growth factor, pg/mL 41 16.8 14.89 (4.5) 14.64 (4.2) 14.95 (4.2) 0.99
sFlt1/PlGF Ratio, ratio 41 / 6.29 (1.6) 6.4 (1.6) 6.4 (1.6) 0.99
Data are presented as median and interquartile range. P < 0.05 was considered statistically significant. *Amount of individual 
samples used for calculation. In those parameters where this value is less than 41, some of the samples had measured values 
below the measuring range of the respective assay. The number of excluded samples, where applicable, are shown in parentheses. 
†All assays were performed on a COBAS 8000 instrument (Roche Diagnostics) using only proprietary reagents. CVs of day-to-day 
QC control values of the respective parameter. CV – coefficient of variation.
Table 2. Comparison of laboratory values measured in serum for different centrifugation conditions
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plasma and Table 2 for analytes measured in se-
rum). As some of the parameter values were nor-
mally distributed while others were not, we chose 
to depicture all values as median and interquartile 
range (IQR). 
Almost no parameters showed any significant dif-
ferences after overall multiple testing corrections. 
Only lactate-dehydrogenase (LD) and measure-
ments of fHb in serum (fHb_S) and plasma (fHb_P) 
showed respective overall multiple testing-cor-
rected P-values of less than 0.05 (Table 1 and Table 
2). A more detailed analysis of LD results revealed 
that the observed differences in measurements 
originated from the tube types (LiHepGel and Li-
HepBar) irrespective of the centrifugation condi-
tions (Figure 2A). Bicarbonate (BIC) measurements, 
which were non-significant after overall multiple-
testing correction (P = 0.286), also showed slight 
yet significant differences when comparing tube 
types (Figure 2B). Measurement of fHb_P and 
fHb_S differed between tube types and also be-
tween centrifugation settings (Figure 2C and 2D). 
When testing for clinical significance of these dif-
ferences using the agreement analysis and a cut-
off of 11.4% (total allowable error according to 
Ricos criteria) for LD, the coverage probability to 
get the same result in LiHepBar vs LiHepGel tubes 
was ~ 60% and ~ 50% for centrifugation at 2000xg 
for 10 minutes and 3000xg for 5 minutes, respec-
tively. This means that in both cases we did not get 
an agreement between the measurements (the 
probability of values differing between these 
tubes by more than 11.4% at the same centrifuga-
tion setting is greater than 40%) and differences in 
LD measurements between LiHepGel and LiHep-
Bar tubes are most probably to be considered clin-
ically significant.
Discussion
In our study we could show that apart from fHb, 
none of the 77 analytes investigated differed sig-
nificantly between centrifugation settings (Table 
1, Table 2 and Figure 2). Looking more closely into 
these fHb differences we found that the higher 
centrifugation speed of 3000xg is associated with 
higher fHb concentrations (Figure 2C comparison 
3-5 and figure 2D comparisons 6-8), as already 
mentioned by Lippi et al. (1). However, when re-
ducing the time of centrifugation to 5 minutes also 
at 3000xg, these significances were diminished 
(Figure 2D comparisons 6-7) or even vanished (Fig-
ure 2C comparison 3-4). As these differences in 
fHb values between centrifugation settings were 
rather small and did not seem to have any influ-
ence on the tested clinical chemistry analytes, our 
findings suggest that respective samples for these 
analyses can be centrifuged at 3000xg for 7 or 5 
minutes without a significant alteration of test re-
sults. However, a raise in fHb even on a low level 
might have impact on analytical outcome if this in-
crease contributes to a final fHb concentration 
above an analyte specific haemolysis cut-off, sub-
sequently leading to a deletion of the respective 
result. 
In order to compare our results to other studies, 
we scanned the literature for evidence based rec-
ommendations and found these to be very scarce 
regarding clinical chemical analytes, finding only 
expert opinion suggestions ranging from 10 to 20 
minutes and 1500 to 3000xg at 15 to 25 °C, respec-
tively (6-10). For other parameters such as coagula-
tion analyses however, several studies have been 
undertaken aiming at reducing centrifugation 
time at higher g-forces (3,4,17,18,27,28). Consider-
ing the potential analytical consequences, it seems 
odd that no real standardization has been 
achieved for this step while the analytical process-
es are constantly improved and accurately con-
trolled. However, there was one investigation car-
ried out by Møller et al. in which nine selected pa-
rameters as well as haemolysis, lipemia and icterus 
index were measured in serum and lithium hepa-
rin sample pairs from 40 patients. Each of these 
sample pairs were centrifuged at 2200xg for 10 
minutes and at 3000xg for 5 minutes (19). Similar 
to our findings, the authors could show a good 
correlation of analyses. However, conflicting with 
our data, they found LD measurements to increase 
by 6.3% on average at higher centrifugation 
speed. Maybe the difference in study population 
contributed to this fact, as the authors collected 
blood from hospitalized patients whereas we drew 
blood from healthy volunteers with lower LD rang-
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Figure 2. Comparison of absolute results of lactate-dehydrogenase (A), bicarbonate (B), free haemoglobin in plasma (C) and serum 
(D) between centrifugation settings and tube types. Scales on the y-axis represent differences in absolute values of the respective 
analyte. IDs on the x-axis represent the different centrifugations settings: 1 – LiHepBar 2000xg/10min; 2 – LiHepBar 3000xg/5min; 3 
– LiHepGel 2000/10min; 4 – LiHepGel 3000xg/5min; 5 – LiHepGel 3000xg/7min; 6 – Serum 2000xg/10min; 7 – Serum 3000xg/5min; 
8 – Serum 3000xg/7min. *P < 0.05; **P < 0.01; ***P < 0.001. P-values < 0.05 were considered statistcally significant.
es. Also the analytical platform differs as we per-
formed analyses on a Roche COBAS system and 
Møller et al. used an Abbott Architect system, in 
which haemolysis is reported in levels rather than 
as quantitative value (29). A statistical evaluation 
of these levels therefore may differ from ours.  
In combination with findings of Sedille-Mostafaie et 
al. demonstrating that blood for coagulation test-
ing can be centrifuged at 3000xg for 7 minutes 
without altering measurement values in a broad va-
riety of haemolysis analytes, samples for clinical 
chemistry and coagulation analyses could eventu-
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ally be centrifuged simultaneously (16). As many 
laboratories process samples using automated pro-
cesses, combining pre-analytical and analytical pro-
cedures, this could help reducing intra-laboratory 
TAT as well as the number of centrifuges needed.
Besides these findings we also evaluated the newly 
introduced BD Barricor tubes (LiHepBar), which use 
a mechanical element to separate plasma from cel-
lular components during centrifugation. Compar-
ing measurements between centrifugation settings 
in these tubes, we did not find a significant differ-
ence in any of the tested analytes, including fHb. 
However, comparing analysis results between Li-
HepBar and the commonly used LiHepGel tubes, 
we found differences in fHb, LDH and BIC measure-
ments, performed in plasma retrieved from identi-
cal centrifugation settings (Figure 2 A-C). Since the 
mechanical separator within the LiHepBar tubes al-
lows cellular blood components to pass during the 
entire centrifugation process and gel separators in 
the respective tubes occlude this passage already at 
an early stage of centrifugation, we hypothesized 
that differences in residual cell count may be the 
reason for the disagreement in fHb and LDH values 
between these two tubes. In a small explorative ex-
periment we could strengthen our assumption that 
LDH levels may be increased upon cellular release 
(data not shown), however, a separate study would 
be needed to conclusively prove this causal rela-
tionship. Nevertheless, according to our data, sepa-
rate LDH reference values for LiHepBar tubes ap-
pear to be necessary. 
For the minor, yet significant BIC differences of 
about 1 mmol/L between these tubes we could 
not find a definite reason. Although respective 
samples in this study were treated identically, we 
assume that the exposure to air in these tubes or 
differences in proceeding cellular metabolism 
might be contributing to this fact. However, as we 
could not find similar results in current literature, 
we were not able to confirm or compare our find-
ings.
As limitation to this study, we want to mention the 
fact that analyses, which are only increased in cer-
tain medical conditions (hsTnT, RF, ßHCG, PAPP-A) 
could not be investigated properly, since only 
healthy volunteers were tested. Subsequently, we 
could also not cover specific medical conditions 
possibly affecting sample stability in different cen-
trifugation conditions.
In conclusion, in this study, we provide evidence 
that samples for the measurement of 77 clinical 
chemistry analytes may be centrifuged at 3000xg 
for 7 or 5 minutes without any impact on test re-
sults compared to centrifugation at 2000xg for 10 
minutes, yielding a benefit of up to 5 minutes in 
intra-laboratory TAT. As residual leucocyte count, 
fHb and subsequently lactate dehydrogenase re-
sults are lower in the BD Barricor tubes, a new LDH 
reference range might be necessary when using 
these tubes.
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